Evommune filed to go public to raise capital for development of two mid‑stage assets targeting chronic inflammatory and atopic diseases. The company seeks proceeds to advance EVO756, an oral MRGPRX2 antagonist for chronic spontaneous urticaria and atopic dermatitis, and EVO301, an IL‑18 neutralizing fusion protein in Phase 2 testing. Evommune reported prior private financings and a cash runway into mid‑2026; it told regulators that late‑stage readouts and further trials are planned with proceeds. Management framed the IPO as a path to fund pivotal trials and broaden the company’s therapeutic indications if Phase 2 results are positive. Investors will watch upcoming Phase 2 readouts — EVO756 and EVO301 are scheduled for data in 2026 — to gauge whether Evommune’s oral and biologic modalities can differentiate in crowded inflammatory‑disease markets.